Menu
Search
|

Menu

Close
X

Cerecor Inc CERC.OQ (NASDAQ Stock Exchange Capital Market)

4.66 USD
+0.04 (+0.87%)
As of Jul 20
chart
Previous Close 4.62
Open 4.62
Volume 13,796
3m Avg Volume 32,947
Today’s High 4.80
Today’s Low 4.62
52 Week High 5.72
52 Week Low 0.52
Shares Outstanding (mil) 26.05
Market Capitalization (mil) 28.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
28
FY16
1
FY15
0
EPS (USD)
FY18
-0.124
FY17
0.517
FY16
-1.883
FY15
-1.216
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
27.69
5.73
Price to Book (MRQ)
vs sector
5.00
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
19.38
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-210.84
14.61
Return on Equity (TTM)
vs sector
-265.70
16.34

EXECUTIVE LEADERSHIP

Uli Hacksell
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Peter Greenleaf
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Isaac Blech
Vice Chairman of the Board, Since 2012
Salary: --
Bonus: --
Joseph Miller
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Jamie Harrell
Executive Vice President of Marketing and Investor Relations, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

400 E Pratt St Ste 606
BALTIMORE   MD   21202-3126

Phone: +1410.5228707

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

SPONSORED STORIES